Identifai Genetics Valuation Multiples

Identifai Genetics is valued at $47M as of November 2026.

Identifai Genetics Overview

About Identifai Genetics

Identifai Genetics Ltd is engaged in the development, validation and commercial deployment of Windrose, a genome-wide non-invasiveprenatal screening platform. The Group's primary focus at this stage is completing CLIA registration and the analytical validation of Windrose, advancing its U.S. multicentre clinical validity study, and preparing for commercial launch in collaboration with Inocras. The Group's product, Windrose, is a first-trimesternon-invasive prenatal test that provides cfDNA-based fetal risk assessment.


Founded

2026

HQ

Australia

Employees

N/A

Financials (Last FY)

Revenue: -
Net Income: -

EV

$46M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Identifai Genetics Stock Performance

Identifai Genetics has current market cap of $47M, and enterprise value of $46M.

Market Cap Evolution


Identifai Genetics' stock price is $0.25.

See more trading valuation data for Identifai Genetics
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$46M$47M-0.0%-0.0%---

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Identifai Genetics Valuation Multiples

Identifai Genetics Financial Valuation Multiples

As of November 3, 2026, Identifai Genetics has market cap of $47M and EV of $46M.

LTMLast FY202320242025202620272028

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Identifai Genetics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Valuation Multiples Across 230+ Verticals

Identifai Genetics Competitors

Identifai Genetics competitors include EDX Medical Group, Abingdon Health, Osang Healthcare, Davion Healthcare, Cryosite, Lumos Diagnostics Hldgs, Pangaea Oncology, Atlantic International, iNtRON Biotechnology and Cleo Diagnostics.

Most Identifai Genetics public comparables operate across Diagnostics & Genomics, BioTech, HealthTech, FemTech and DeepTech.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
EDX Medical Group$442K($7M)89.3x-(5.3x)-
Abingdon Health$15M($2M)3.4x3.3x(29.3x)(34.3x)
Osang Healthcare$96M$8M0.6x-6.5x-
Davion Healthcare-($921K)--(46.8x)-
Cryosite$12M$3M3.9x3.7x15.2x14.1x
Lumos Diagnostics Hldgs$13M($412K)2.4x2.1x(77.6x)(5.2x)
Pangaea Oncology$16M($1M)3.9x3.7x(60.3x)(20.0x)
Atlantic International$436M($44M)1.4x1.4x(13.5x)-

This data is available for Pro users. Sign up to see all Identifai Genetics competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Identifai Genetics

When was Identifai Genetics founded?Identifai Genetics was founded in 2026.
Where is Identifai Genetics headquartered?Identifai Genetics is headquartered in Australia.
Who is the CEO of Identifai Genetics?Identifai Genetics' CEO is Eyal Miller.
Is Identifai Genetics publicly listed?Yes, Identifai Genetics is a public company listed on Australian Securities Exchange.
What is the stock symbol of Identifai Genetics?Identifai Genetics trades under ID1 ticker.
When did Identifai Genetics go public?Identifai Genetics went public in 2026.
Who are competitors of Identifai Genetics?Identifai Genetics main competitors include EDX Medical Group, Abingdon Health, Osang Healthcare, Davion Healthcare, Cryosite, Lumos Diagnostics Hldgs, Pangaea Oncology, Atlantic International, iNtRON Biotechnology, Cleo Diagnostics.
What is the current market cap of Identifai Genetics?Identifai Genetics' current market cap is $47M.
Is Identifai Genetics profitable?No, Identifai Genetics is not profitable.
How many companies Identifai Genetics has acquired to date?Identifai Genetics hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Identifai Genetics has invested to date?Identifai Genetics hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Identifai Genetics

Lists including Identifai Genetics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial